CBT
Cannabitriol · CBT · Discovered 1966
Learn about CBT (Cannabitriol), a rare non-psychoactive cannabinoid found in cannabis. Explore what is currently known about its structure, occurrence in the plant, and limited but emerging research.
Psychoactive
No
Discovered
1966
Effects
3 documented
Benefits
1 studied
Overview
Cannabitriol (CBT) is a rare, naturally occurring cannabinoid first identified in cannabis in the mid-1960s. It is one of the least-studied cannabinoids despite being known for decades, primarily because it occurs in extremely low concentrations in most cannabis cultivars and has historically been difficult to isolate in quantities sufficient for thorough pharmacological investigation. CBT exists in several structural variants, with the most common being (-)-(9R,10R)-trans-cannabitriol.
CBT is structurally related to THC but features a hydroxyl group modification that dramatically alters its pharmacological properties. Unlike THC, CBT does not produce psychoactive effects and has very low affinity for CB1 receptors. The compound appears to be a minor metabolite or degradation product in certain cannabis chemotypes, and its natural concentrations are typically too low to contribute meaningfully to the overall effects of cannabis consumption.
Research on CBT is extremely sparse, with only a handful of published studies examining its properties. Early investigations noted that CBT could lower intraocular pressure in animal models, suggesting potential glaucoma applications, but this finding was never followed up with comprehensive studies. The current wave of interest in minor cannabinoids may eventually bring CBT into sharper research focus, but as of 2025, it remains one of the most poorly characterized cannabinoids in the scientific literature.
Mechanism of Action
The mechanism of action of CBT is largely uncharacterized. Limited data suggests it has minimal interaction with CB1 and CB2 cannabinoid receptors, consistent with its non-psychoactive nature. Early research indicated potential activity at receptors involved in intraocular pressure regulation, though the specific molecular targets were not identified. CBT's structural relationship to THC suggests possible interaction with TRP channels and other targets in the endocannabinoid system, but these have not been experimentally verified. Further pharmacological characterization is needed to understand CBT's receptor binding profile and therapeutic potential.
Therapeutic Effects
Potential Benefits
Glaucoma
Very limited preclinical evidence. Early studies noted CBT's potential to reduce intraocular pressure in animal models, but these findings have not been replicated or expanded upon in modern research. The mechanism is unknown.
Side Effects & Risks
- ⚠No significant side effects documented due to extremely limited research
- ⚠Safety profile is essentially unknown
- ⚠Not available in consumer products for practical assessment
Concentration & Sources
Typical Concentration
Trace amounts (less than 0.1%) in most cannabis cultivars; not commercially available as an isolated product
Found In
Trace quantities in various cannabis cultivars. Not commercially available as an isolated cannabinoid product. May be present in small amounts in full-spectrum cannabis extracts.
Legal Status
Not specifically regulated. Legal in most jurisdictions as a non-psychoactive, naturally occurring cannabis compound. Not scheduled as a controlled substance anywhere.
Research Summary
CBT is one of the least researched cannabinoids known to science. First identified in the 1960s, it has been the subject of only a small number of published studies over the past six decades. The most notable early finding was its potential to reduce intraocular pressure, but this was never pursued with the rigor needed for clinical development. Modern analytical techniques have improved the ability to detect and quantify CBT in cannabis samples, which may eventually facilitate more thorough investigation. As the minor cannabinoid research field expands, CBT may receive the attention needed to determine whether its unique structure offers untapped therapeutic potential.
Related Cannabinoids
CBT FAQ
What is CBT cannabinoid?
CBT (cannabitriol) is a rare, naturally occurring cannabinoid found in cannabis in very small quantities. It is non-psychoactive and structurally related to THC but with modifications that prevent it from producing a high. CBT is one of the least studied cannabinoids, with limited research on its effects and therapeutic potential. It was first identified in the 1960s.
Does CBT get you high?
No, CBT does not produce psychoactive effects. Its structural modifications compared to THC prevent significant binding to CB1 receptors in the brain, which is required for psychoactive effects. CBT is considered non-intoxicating at any concentration found in natural cannabis.
Is CBT available in products?
As of 2025, CBT is not widely available as an isolated consumer product. Its extremely low natural concentration in cannabis makes commercial extraction impractical, and no significant market demand has driven synthetic production. CBT may be present in trace amounts in full-spectrum cannabis extracts, but not in quantities that would produce notable individual effects.
What are the benefits of CBT?
The benefits of CBT are largely unknown due to limited research. Early preclinical studies suggested it might help reduce eye pressure (relevant to glaucoma), but this was never confirmed in comprehensive research. More studies are needed to determine whether CBT has meaningful therapeutic applications. Its non-psychoactive nature means it would not produce a high if used therapeutically.
Continue Exploring
Disclaimer: Cannabinoid information is provided for educational purposes only. Medical benefits are based on published research and are not intended as medical advice. Individual responses to cannabinoids vary. Always consult a healthcare professional before using cannabis for medical purposes. Legal status information is current as of publication but may change — verify your local laws.